MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses
Open Access
- 30 April 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 30 (12), 1477-1485
- https://doi.org/10.1093/eurheartj/ehp127
Abstract
To report the 4-month angiographic and 6-month clinical follow-up in first-in-man study using the tacrolimus-eluting bioabsorbable polymer-coated cobalt–chromium MAHOROBA™ stent. A total of 47 patients with either stable angina or unstable angina, or silent myocardial ischaemia, based on a de novo coronary stenosis that could be covered by a single 18 mm stent in a native coronary artery with a diameter between 3.0 and 3.5 mm were enrolled at three sites. The primary endpoint was in-stent late loss at 4 months. The secondary endpoints include %volume obstruction of the stents assessed by intravascular ultrasound (IVUS) at 4 months and major adverse cardiac events (MACE) at 6 months. Forty-seven patients were enrolled. Procedural success was achieved in 97.9%. At 4-month follow-up, in-stent late loss was 0.99 ± 0.46 mm, whereas in-stent %volume obstruction in IVUS was 34.8 ± 15.8%. At 6 months, there were no deaths, but 2 patients suffered from a myocardial infarction and 11 patients required ischaemia-driven repeat revascularization. The composite MACE rate was 23.4%. This tacrolimus-eluting stent failed to prevent neointimal hyperplasia, despite the theoretical advantages of the tacrolimus, which has less inhibitory effects on endothelial cells than smooth muscle cells.Keywords
This publication has 29 references indexed in Scilit:
- Determination of sirolimus in rabbit arteries using liquid chromatography separation and tandem mass spectrometric detectionBiomedical Chromatography, 2007
- Comparison of in vivo acute stent recoil between the bioabsorbable everolimus‐eluting coronary stent and the everolimus‐eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trialsCatheterization and Cardiovascular Interventions, 2007
- Effects of Tacrolimus or Sirolimus on Proliferation of Vascular Smooth Muscle and Endothelial CellsJournal of Cardiovascular Pharmacology, 2006
- Coronary-Artery StentsNew England Journal of Medicine, 2006
- Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosisCatheterization and Cardiovascular Interventions, 2004
- Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbitsCatheterization and Cardiovascular Interventions, 2003
- The Mechanism of Action of Cyclosporin A and FK506Clinical Immunology and Immunopathology, 1996
- Recoil following wiktor stent implantation for restenotic lesions of coronary arteriesCatheterization and Cardiovascular Diagnosis, 1994
- Angiographic predictors of recurrence of restenosis after Wiktor stent implantation in native coronary arteriesThe American Journal of Cardiology, 1993
- Morphologic change in coronary artery stenosis with the medtronic Wiktor™ stent: Initial results from the core laboratory for quantitative angiographyCatheterization and Cardiovascular Diagnosis, 1991